mRNA Network: Solution for Tracking Chemotherapy Insensitivity in Small-Cell Lung Cancer

Peixin Chen; Shengyu Wu; Jia Yu; Xuzhen Tang; Chunlei Dai; Hui Qi; Junjie Zhu; Wei Li; Bin Chen; Jun Zhu; Hao Wang; Sha Zhao; Hongcheng Liu; Peng Kuang; Yayi He

doi:10.1155/2021/2105176

mRNA Network: Solution for Tracking Chemotherapy Insensitivity in Small-Cell Lung Cancer

J Healthc Eng. 2021 Sep 28:2021:2105176. doi: 10.1155/2021/2105176. eCollection 2021.

Authors

Peixin Chen^{1

2}, Shengyu Wu^{1

2}, Jia Yu^{1

2}, Xuzhen Tang³, Chunlei Dai³, Hui Qi³, Junjie Zhu⁴, Wei Li^{1

2}, Bin Chen^{1

2}, Jun Zhu^{1

2}, Hao Wang^{1

2}, Sha Zhao^{1

2}, Hongcheng Liu⁴, Peng Kuang⁵, Yayi He^{1

2}

Affiliations

¹ Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.
² Medical School, Tongji University, Shanghai 200433, China.
³ Oncology and Immunology BU, Research Service Division, WuXi Apptec, Shanghai, China.
⁴ Department of Surgery, Shanghai Pulmonary Hospital, Tongji University, Tongji University School of Medicine, Shanghai 200433, China.
⁵ Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.

Abstract

Background: Small-cell lung cancer (SCLC) has poor prognosis and is prone to drug resistance. It is necessary to search for possible influencing factors for SCLC chemotherapy insensitivity. Therefore, we proposed an mRNA network to track the chemotherapy insensitivity in SCLC.

Methods: Six samples of patients with SCLC were recruited for RNA sequencing. TopHat2 and Cufflinks were used to make differential analysis. Functional analysis was applied as well. Finally, multidimensional validation was applied for verifying the results we obtained by experiment.

Results: This study was a trial of drug resistance in 6 SCLC patients after first-line chemotherapy. The top 10 downregulated genes differentially expressed in the chemo-insensitive group were SERPING1, DRD5, PARVG, PRAME, NKX1-1, MCTP2, PID1, PLEKHA4, SPP1, and SLN. Cell-cell signaling by Wnt (p=6.98E - 21) was the most significantly enriched GO term in biological process, while systemic lupus erythematosus (p=6.97E - 10), alcoholism (p=1.01E - 09), and transcriptional misregulation in cancer (p=0.00227988) were the top three ones of KEGG pathways. In multiple public databases, we also highlighted and verified the vital role of glycolysis/gluconeogenesis pathway and corresponding genes in chemo-insensitivity in SCLC.

Conclusion: Our study confirmed some SCLC chemotherapy insensitivity-related genes, biological processes, and pathways, thus constructing the chemotherapy-insensitive network for SCLC.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't
Retracted Publication

MeSH terms

Cell Line, Tumor
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
RNA, Messenger
Small Cell Lung Carcinoma* / drug therapy
Small Cell Lung Carcinoma* / genetics

Substances

RNA, Messenger